Abstract
Basal as well as xenobiotic-induced expression of the main enzymes from phase I and phase II of drug metabolism is confined to the perivenous areas of the mammalian liver lobule. Whereas signal transduction pathways that govern xenobiotic-induced expression of these enzymes via ligand-activated transcription factors such as constitutive androstane receptor (CAR) or the aryl hydrocarbon receptor (AhR) have been intensively studied, the mechanisms regulating zone-specific basal expression of genes related to drug metabolism and preferential response of perivenous hepatocytes to xenobiotic inducers are still largely unknown. Recent publications by our and other groups point to an important role for the Wnt/β-catenin pathway in the maintenance of the perivenous hepatocyte gene expression profile including the main hepatic detoxification enzymes, and β-catenin signaling was recently implicated in the expression of several cytochrome P450 isoenzymes. To analyze, whether the β-catenin pathway would also affect inducible expression of drug-metabolizing enzymes, mice with liver-specific knockout of the Ctnnb1 gene (encoding β-catenin) were treated with different model inducers of xenobiotic metabolism. Knockout of β-catenin led to alterations in basal expression of most drug metabolism-related genes analyzed and resulted in strongly diminished responses to agonists of CAR-, AhR-, and nuclear factor erythroid-related factor 2-dependent transcription. Taken together, the data presented in this study indicate that β-catenin not only regulates basal expression of drug-metabolizing enzymes but also determines the magnitude and hepatic localization of response to xenobiotic inducers in vivo.
Footnotes
-
This study was supported by the Deutsche Krebshilfe [Grant 106356].
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.108.026179.
-
ABBREVIATIONS: P450, cytochrome P450; CAR, constitutive androstane receptor; AhR, aryl hydrocarbon receptor; TCDD, 2,3,7,8-tetrachloro-p-dibenzodioxin; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene; PB, phenobarbital; 3MC, 3-methylcholanthrene; PCN, pregnenolone-α-carbonitrile; BHA, butylated hydroxyanisole; RT-PCR, reverse transcription-polymerase chain reaction; GST, glutathione S-transferase; G6P, glucose-6-phosphatase; Ugt, UDP-glucuronosyl-transferase; PXR, pregnane-X-receptor; PPAR, peroxisome proliferator-activated receptor; Nrf2, nuclear factor erythroid-related factor 2; Ephx1, microsomal epoxide hydrolase; Nqo, NAD(P)H-quinone-oxidoreductase.
-
↵
The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
- Received December 16, 2008.
- Accepted February 20, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|